Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40

NCT00216138 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT00216138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40
Lead sponsor
Hoosier Cancer Research Network
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2004
Completion date
September 30, 2007
Enrollment
19 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer